News

Thursday, February 7, 2019

Fagron is evolving together with compounding offering new possibilities for prescribers and compounding pharmacies.

Monday, January 7, 2019

Together we move from a solution of a personalized medication to solutions of personalized medicine in order to prevent, diagnose and treat.

Fagron US announces stability data on LETS GEL KIT™ for rapid topical anesthesia

Tuesday, November 28, 2017

New study supports extended beyond use dating in Fagron unit dose syringe

Fagron US announces launch of LETS GEL KIT™ for rapid topical anesthesia

Tuesday, July 18, 2017

New unit-dose gel alternative to TAC available for suture preparations.

Oseltamivir phosphate in SyrSpend® SF for the flu season

Wednesday, December 21, 2016

Oseltamivir phosphate 6 mg/ml in SyrSpend® SF PH4 is currently compatible for at least 60 days and the study is still running until 90 days.

Parabens in oral pharmaceutical preparations

Wednesday, December 21, 2016

Fagron’s trademark vehicle SyrSpend® SF does not contain any parabens or other unwanted excipients and is therefore suitable for a broad group of patients, including children.

Transdermal Oxandrolone: Ex vivo Percutaneous Absorption Study

Monday, October 3, 2016

Transdermal Oxandrolone: Ex vivo Percutaneous Absorption Study

World pharmacist day – 25th of September 2016

Thursday, September 22, 2016

Pharmacists have a vital role in the outcome of pharmacological therapies and ultimately strive to improve patients quality of life.

European Commission bans MI in leave-on products

Tuesday, September 20, 2016

The ban of MI in leave-on products by the EC underlines the importance of ingredient safety.

Fagron medical device - Nourisil™ MD

Thursday, September 8, 2016

Fagron is very happy to announce that we have launched the class I registered medical device Nourisil™ MD

Consulfarma congress Brazil 2016

Monday, August 8, 2016

Fagron Brazil, Fagron Technologies, Pharma Nostra, Florien and Via Farma have all exhibited at Consulfarma 2016

Atopic Schools in Belgium

Wednesday, July 20, 2016

Fagron Belgium received many positive reactions on the atopic schools initiative and FAD products.

SyrSpend® SF in clinical trials

Tuesday, June 28, 2016

Fagron is happy to announce that SyrSpend® SF is currently being recognized by large pharmaceutical companies for its quality and compatibility, as is demonstrated by the fact that two big pharmaceutical companies are using the product for their clinical

Public consultation on MI announced by EC

Monday, May 2, 2016

The European Commission (EC) announced the public consultation on methylisothiazolinone (MI) in rinse-off cosmetic products proposing a restriction of its use and a ban for the use in leave-on products.

EPSA – Drug therapy for special patient groups

Friday, April 22, 2016

Fagron was invited to speak at the 39th annual congress of the European Pharmaceutical Students Association (EPSA) in Helsinki, Finland.

SyrSpend® SF – Scientific evidence for another 10 APIs

Tuesday, April 5, 2016

In the study published in the April edition of Die Pharmazie, the physical and chemical stability of another 10 APIs was studied in SyrSpend® SF PH4 liquid

SyrSpend® SF – Proven stability for 10 additional APIs

Tuesday, March 29, 2016

SyrSpend® SF is a unique ready-to-use suspending vehicle that has been gaining momentum in compounding pharmacies worldwide.

Oseltamivir phosphate in SyrSpend® SF PH4

Monday, March 21, 2016

Influenza is a major health problem that can result in hospitalization

Meet Fagron at the 21st EAHP in Vienna

Thursday, March 3, 2016

For the 21st time the European Association of Hospital Pharmacists (EAHP) organizes the largest annual congress on hospital pharmacy in Europe.

Compounding as a solution for drug shortages

Monday, February 8, 2016

Drug shortages are an increasing worldwide problem that cause numerous difficulties for prescribers, pharmacists, patients, and federal regulators.

Fagron - Global expertise for local needs

Friday, January 22, 2016

For all local requests Fagron creates a customized solution for your business challenge or opportunity

SyrSpend® SF - Stability data for 20 commonly used API’s now available

Wednesday, January 6, 2016

The results of two studies recently published include data for 20 commonly used API’s from different pharmaceutical classes

Happy holidays and best wishes for a wonderful new year

Tuesday, December 22, 2015

Seasons Greetings. In warm appreciation of our association during the past year, we extend our very best wishes for a blissful holiday season.

Expanding SyrSpend® SF’s scientific stability database

Wednesday, November 25, 2015

A new article has recently been published in the high-impact Journal of Pharmaceutical and Biomedical Analysis

Pentravan®: new route of administration for innovative treatments

Tuesday, November 10, 2015

Pentravan® has demonstrated to be an effective vehicle for the administration of hormones via the vaginal mucosa.

Creating the world's largest compatibility library for a single oral liquid vehicle

Monday, October 26, 2015

For patients that require non-standard doses, experience swallowing difficulties or receive medication via enteral feeding tubes, compounding oral liquid dosage forms is common and important pharmacy practice.

Fagron Specialty Pharma Services: expansion into nuclear, pain and intrathecal customized medication

Monday, August 31, 2015

Fagron is proud to welcome the pharmaceutical company AnazaoHealth Corporation into the Fagron Family...

Fagron Academy: education on pharmaceutical compounding

Monday, July 20, 2015

Fagron Academy offers comprehensive practical and lecture-based pharmacy compounding education courses for prescribers and pharmacists.

Fagron reshapes the U.S. Sterile Compounding Industry

Monday, July 13, 2015

Fagron North America will open one of the largest 503B human drug outsourcing facilities in the U.S. in November...

Fagron Advanced Derma, free of harmful and controversial ingredients

Friday, April 10, 2015

Excipients are essential ingredients of almost any dermatological product and required to assure numerous properties of the final preparation, such as...

Meet Fagron!

Friday, February 6, 2015

Sign up for our ‘Meet Fagron’ inhouse day on 12 May and discover what it means to work at a global R&D scientific pharmaceutical company.

SAVE THE DATE! Farmadays, 17-19 ottobre 2014, Verona

Wednesday, October 15, 2014

Vi aspettiamo a Farmadays, allo stand n. 98, con le nostre proposte innovative per la galenica

25 September: World Pharmacists Day

Thursday, September 25, 2014

On 25 September the world pays attention to the role of the pharmacist in improving health in every corner of the world. This years’ theme is:

Six new, innovative Fagron Advanced Derma vehicles!

Friday, September 19, 2014

Fagron Advanced Derma is a total solution for the treatment of dermatological diseases and conditions and now includes a range of eleven skin-friendly vehicles for different skin types and areas.

Pentravan® performance: additional scientific evidence

Monday, August 18, 2014

There is an increasing interest for Pentravan® transdermal cream in scientific literature. A new publication in the most recent edition of the International Journal of Pharmaceutical Compounding concludes that human female sexual hormones incorporated in

Innovations in dermatology and pain management

Tuesday, July 8, 2014

Fagron Advanced Derma has been introduced in the first half of 2014. This innovative concept is already being used by dermatologists on three continents in their treatment plans.

Fagron Advanced Derma and SyrSpend® SF formularies available on Compounding Matters!

Wednesday, May 28, 2014

Over 200 unique compounding instructions for more than 120 different active pharmaceutical ingredients (APIs) in Fagron’s global Advanced Derma and SyrSpend® SF bases have been uploaded to the Compounding Matters database.

New CapsiCards® System released

Friday, March 28, 2014

A unique combination of the CapsiCards® Machine and the CapsiCards®.The total solution for easy and efficient capsule filling.

Apply now for our Global Management Program!

Wednesday, March 26, 2014

Do you want your ticket to a successful international career in an exciting fast-growing company?

Meet Fagron For Young Potentials!

Tuesday, January 7, 2014

Have you always been curious to see and hear what Fagron is all about?

Fagron Advanced Derma

Thursday, January 2, 2014

Fagron has created a revolutionary standard for advanced, individualised dermatological therapy and care.

Acquisition of Alternate Technologies in Brazil

Thursday, November 7, 2013

Innovative software solutions for pharmaceutical compounding, ready to be launched globally

Falsified Medicines Directive

Wednesday, June 19, 2013

Fagron is ready for compliancy with the Falsified Medicines Directive (2011/62/EU).

Fagron: Acquisition of United States based Freedom Pharmaceuticals

Thursday, April 25, 2013

Fagron creates a strong and nation-wide U.S. coverage, immediately delivering extra value to customers

Fagron enters into a partnership with NAFA Medical in Saudi Arabia

Tuesday, April 9, 2013

In March 2013, Fagron entered into a partnership with NAFA Medical in Saudi Arabia for the purpose of introducing Fagron’s products and concepts onto the Saudi market

Fagron strengthens its position in the United States through the acquisition of B&B Pharmaceuticals

Thursday, December 20, 2012

Fagron announces today that it has signed an agreement to acquire B&B Pharmaceuticals

Fagron strengthens market leadership with acquisitions in Brazil, Colombia and Scandinavia

Tuesday, November 13, 2012

Fagron strengthens market leadership with acquisitions in Brazil, Colombia and Scandinavia

European introduction of Pentravan®

Tuesday, June 19, 2012

Pentravan® (penetration enhanced vanishing cream) is a transdermal delivery system for drugs (active pharmaceutical ingredients; APIs) and is intended for use as a cream base for pharmaceutical compounding.

Fagron Academy

Monday, January 23, 2012

Fagron founded Fagron Academy in 2011.

Fagron gains market leadership in Poland through the acquisition of Pharma Cosmetic

Tuesday, December 27, 2011

Fagron Group announces today that it has signed an agreement for the acquisition of Polish company Pharma Cosmetic, a leading supplier of pharmaceutical raw materials for compounding pharmacies in Poland.

Fagron gains market leadership in biggest compounding market in the world by acquisition of the Brazilian company Pharma Nostra

Sunday, December 11, 2011

Fagron Group announces today that it has signed an agreement for the acquisition of the Brazilian Pharma Nostra, a leading supplier of raw materials for pharmaceutical compounding to pharmacies in Brazil.

Introduction of Fagron Imprinta in Belgium

Friday, September 2, 2011

This concept, developed in Belgium, will be introduced in other European countries during 2012.

Foundation of Fagron Argentina

Thursday, September 1, 2011

After a study of the Argentinean market, Fagron Group decided to start a greenfield operation in Buenos Aires.

Acquisition of Pharma Assist, a leading Dutch compounding pharmacy

Friday, July 8, 2011

Fagron announces today that it has signed an agreement for the acquisition of the Dutch Pharma Cosmetic, a compounding pharmacy that specializes in preparing tailor-made aseptic and high risk compounded products for individual patients.

Strategic acquisition of Brazilian DEG

Monday, December 20, 2010

Fagron secures number 2 position in largest compounding market in the world.

Transition of Gallipot to Fagron US completed

Friday, June 4, 2010

Fagron Group announces today that Gallipot has changed its name to Fagron US, officially ending the transition period that started when Fagron Group acquired the former Gallipot in May 2010.

Fagron announces the acquisition of Gallipot in the US

Monday, May 10, 2010

Gallipot is the perfect platform to launch the Fagron strategy in the US

Extemporaneous preparation in the event of shortage of Tamiflu®/Oseltamivir oral suspension

Wednesday, October 7, 2009

The US Food and Drug Administration (FDA) has approved that, in the event of a shortage of Tamiflu®1/Oseltamivir oral suspension for children, pharmacists should revert to emergency compounding, using Ora-Sweet SF® or Humco Cherry Syrup®.

Fagron launches successful Derma Concept

Monday, March 2, 2009

Fagron’s aim is to offer the most innovative and service-oriented services.

Medicinal cannabis now also distributed exclusively by Fagron in Germany

Monday, December 8, 2008

Following the success of medicinal cannabis in the Netherlands a number of other countries have shown an interest.

Fagron takes over activities of Danish Unikem

Thursday, July 10, 2008

Fagron expands into Scandinavia

Fagron acquires control of Czech Tamda

Thursday, April 24, 2008

Fagron to expand into central and Eastern Europe

Knowledge Search

Search form

Our Innovative Concepts

News archive

Mission & Strategy

Fagron Values

Pharmaceutical compounding

Cases

Fagron Advanced Derma

Code of Conduct & Ethics

Knowledge Search

Search form

Our Innovative Concepts

Compounding Matters

Documents (MSDS & CoA)

Terminology List

Research & Development

Pipeline

Dermatology

Pain

Oral Suspending Vehicles

Quality Management

Quality Activities

Supplier qualifications and audits

Falsified Medicines Directive

Documentation and Records

Fagron Academy

Fagron Foundation

Careers

Fagron Leadership team

News

Fagron History

News

News archive